Genomic medicine in non-small cell lung cancer: paving the path to personalized care.
Lung cancer is the commonest cause of cancer-related mortality and non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer. The prognosis of NSCLC remains poor across all stages, despite advances in staging techniques and treatments. The findings of recent high-throughput mRNA microarray studies have shown potential in refining current NSCLC diagnosis, classification, prognosis and treatment paradigms. Emerging microarray studies of microRNA, DNA copy number and methylation profiles are also providing novel insights into the biology of NSCLC. Currently there are several challenges, such as the reproducibility and cost of microarray platforms that will need to be addressed prior to the implementation of these genomic technologies to routine thoracic oncology practice. In addition, genomic tests (such as prognosis and prediction gene expression signatures) will need to be validated in well designed prospective studies that aim to answer clinically relevant questions. If successful, the integration of microarray-based genomic information with existing clinicopathological models may enhance the ability of clinicians to match the most effective treatment to an individual patient. Such a strategy may improve survival and reduce treatment-related morbidity in NSCLC patients.
The Prince Charles Hospital, The University of Queensland, Brisbane, Queensland, Australia. bajee.sriram@uqconnect.edu.au
Krishna Bajee
KB
Sriram
Jill Everland
JE
Larsen
Ian Anthony
IA
Yang
Rayleen Veronica
RV
Bowman
Kwun Meng
KM
Fong
D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D020869:Gene Expression Profiling; D023281:Genomics; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D009367:Neoplasm Staging / Q000379:methods; D057285:Precision Medicine; D011379:Prognosis